3Jaffe ES, Harris NL, Stein H, et al. pathology and genetics: tumours of haematopoietic and lymphoid tissues (World Health organization classification of tumours) [M]. Lyon: IARC Press, 2003.
4Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietie and lymphoid tissues [M]. 4th ed. Lyon : IARC Press ,2008.
5Cheson BD, Homing SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non- Hodgkin's lymphomas. NCI Sponsored lntemational Working Group[J]. J Clin Oneol, 1999, 17(4) :1244.
6Yang Y, Jia Y, Wang Y, et al. Sequence analysis of EBV immediate-early gene BZLF1 and BRLF1 in lymphomas[J]. J Med Virol, 2014, 86(10) :1788-1795.
7Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels[J]. Cancer, 2013, 119(5) :963-970.
8Ishii H, Ogino T, Berger C, et al. Clinical usefulness of serum EBV DNA levels of BamHl W and LMP1 for Nasal NK/T-cell lymphoma[J]. J Med Virol, 2007, 79(5 ) :562-572.
9Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Ban" vires (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients[Jl. Blood, 2004, 104( 1 ) :243-249.
10Kim HS, Kim KH, Kim KH, et al. Whole blood Epstein-Barr vires DNA load as a diagnostic and prognostic surrogate extranodal natural killer/T-cell lymphoma [J]. Leuk Lymphoma, 2009, 50(5 ) :757-763.
